A method of charging an electronic module of a drug delivery device and a respective charging system. An electronic encoder module may comprise at least one sensor unit, a PCBA with a processor configured to control operation of the at least one sensor unit and to process and/or store signals from the at least one sensor unit, a rechargeable battery connected to the PCBA, and a cap-shaped outer shell at least partially encasing the at least one sensor unit, the PCBA and the battery. The outer shell comprises a lateral surface and a proximally arranged top surface, wherein at least two electrical contacts connected to the battery and/or the PCBA are provided on the lateral surface and/or on the proximally arranged top surface.
This application relates to modified influenza B hemagglutinin polypeptides and nucleic acids, such as messenger ribonucleic acids (mRNAs), encoding the same, as well as compositions comprising the same, vaccines comprising the same, and methods of using the same, such as in the prevention and/or treatment of diseases or conditions caused by influenza B viruses.
A cartridge assembly for a drug delivery device is described. The cartridge assembly includes (i) a cartridge containing a drug, the cartridge including a dispensing end; (ii) a cartridge holder, the cartridge holder defining an interior cartridge holding section, in which the cartridge is arranged within the cartridge holding section; and (iii) a fixing member. The fixing member includes a fixing surface, in particular a radially oriented surface, which is arranged to abut a cartridge surface of the cartridge, in particular a radially oriented surface. The cartridge surface is a proximal surface which faces away from the dispensing end of the cartridge, and the cartridge surface is arranged between the dispensing end of the cartridge and the end opposite of the dispensing end. The fixing member includes a securing surface which is arranged to abut a holder surface of the cartridge holder to prevent removal of the cartridge from the cartridge holder such that the cartridge is permanently secured in the cartridge holder, and the holder surface is a distal surface of the cartridge holder. Further, a drug delivery device and a method for assembling the cartridge assembly are described.
Embodiments of the present disclosure include systems, methods, and non- transitory computer-readable storage media for generating a combined standardized clinical trial database providing a graphical user interface for analysis using the combined standardized clinical trial database. The disclosure of some embodiments includes processes of standardizing and unifying clinical trial data obtained from a variety of database systems that store similar clinical trial data using different datatypes and formats.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
05 - Pharmaceutical, veterinary and sanitary products
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Administration of a program for enabling participants to obtain discounts on products and services; Administration of a discount program for enabling participants to obtain discounts on goods and services through use of a discount membership card; Promoting public awareness of medications and treatments for diabetes; Providing business information in the field of patient relationship management services for the purpose of assisting prospective patients regarding the treatment of disease via a web site; Providing business information in the field of business administration of patient reimbursement programs regarding medical treatment payment plan options for patients undergoing treatment of disease Pharmaceutical preparations for human use; Insulin Providing training in the field of diabetes and injecting insulin; Publication of articles and scientific journals; Educational services, namely, developing, arranging, and conducting educational conferences and programs and providing courses of instruction in the field of healthcare and medicine for health care providers, care givers, health care insurers, payers in the healthcare field, patients with diabetes and related diseases and disorders, and patients with autoimmune diseases; Entertainment services, namely, providing podcasts in the field of healthcare and medicine; Educational services, namely, conducting conferences, training, seminars, congresses, presentations, and workshops in the field of healthcare and medicine and distribution of educational materials in connection therewith, all the foregoing distributed across multiple forms of transmission media including online via the internet and via social network platforms Providing medical information in the field of diabetes; Providing medical information; Medical services; Medical services in the field of diabetes, autoimmune diseases and disorders, and related diseases and disorders, namely, providing medical and psychological support for healthcare professionals, patients with diabetes and related diseases and disorders, and patients with autoimmune diseases and disorders; Providing medical information in the field of prevention and treatment of diabetes, autoimmune diseases and disorders, and diseases and disorders related to diabetes; Providing medical information in the field of diabetes, treatment of the disease, burden of the disease, and pathophysiology of the autoimmune nature of the disease via a website; Providing medical information in the field of diabetes, autoimmune diseases, and related diseases and disorders, and on the prevention and early diagnosis of asymptomatic Type 1 diabetes, to health care providers; Providing medical information in the field of diabetes and autoimmune diseases to patients, health care professionals, and caregivers via electronic media, via the Internet, and via social networks; Providing medical information in the field of life threatening disorders, namely, providing educational information to caregivers and patients in the field of personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, treatment management, all of the aforesaid provided via website or telephone, non-downloadable webinars, and printed material distributed in connection therewith; Providing educational information about healthcare
Described is a medicament container carrier adapted to hold a first medicament container having a first predetermined size and capable of containing more than a first volume of a medicament. The container carrier comprises a body, and an adapter coupled to the body. The adapter is adapted to hold a second medicament container having a second predetermined size different from the first predetermined size and capable of containing no more than the first volume of the medicament.
Described is a medicament container carrier adapted to hold a first medicament container having a first predetermined size and capable of containing more than a first volume of a medicament. The container carrier comprises a body, and an adapter coupled to the body. The adapter is adapted to hold a second medicament container having a second predetermined size different from the first predetermined size and capable of containing no more than the first volume of the medicament.
Described is a medicament container carrier adapted to hold a first medicament container having a first predetermined size and capable of containing more than a first volume of a medicament. The container carrier comprises a body, and an adapter coupled to the body. The adapter is adapted to hold a second medicament container having a second predetermined size different from the first predetermined size and capable of containing no more than the first volume of the medicament.
A system may be configured to self-select provision of a nonprescription drug. Some embodiments may: select a mode of implementing a health survey preapproved by a regulatory body; control, via the selected mode and a processor, a sequence of the health survey; determine, via a processor, whether a user undergoing the survey is authorized to purchase the drug; and responsive to the user being authorized, provide a plurality of ways to make the purchase.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
The present invention relates to an insulin conjugate comprising a human serum albumin binder of Formula (I) and a human insulin analog, wherein the human serum albumin binder of Formula (I) is covalently bound to the human insulin analog in that the terminal carboxy group “a” of the human serum albumin binder of Formula (I) is covalently bound via an amide bond to the epsilon amino group of lysine B29 of the human insulin analog. As well as related aspects such as a pharmaceutical composition, use in medicine, methods for preparing such insulin conjugates and so forth.
The present invention relates to an insulin conjugate comprising a human serum albumin binder of Formula (I) and a human insulin analog, wherein the human serum albumin binder of Formula (I) is covalently bound to the human insulin analog in that the terminal carboxy group “a” of the human serum albumin binder of Formula (I) is covalently bound via an amide bond to the epsilon amino group of lysine B29 of the human insulin analog. As well as related aspects such as a pharmaceutical composition, use in medicine, methods for preparing such insulin conjugates and so forth.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
In one aspect the present disclosure relates to a stopper (100) for insertion into a barrel (151) of an injection device, the stopper (100) comprising: - a stopper body (101) comprising an elastomeric material (102) and a contact surface (104) to sealingly engage with an inside surface (27) of the barrel (151), - a distally facing surface portion (110), - a proximally facing surface portion (130) opposite to the distally facing surface portion (110) and - an intermediate surface portion (120) located between the distally facing surface portion (110) and the proximally facing surface portion (130), - wherein at least one of the distally facing surface portion (110), the proximally facing surface portion (130) and the intermediate surface portion (120) comprises a convex shape.
The disclosure relates to IL-23 receptor inhibitor compounds of formula (I), their pharmaceutical compositions, and their medical uses, for example in the treatment of inflammatory bowel diseases such as Crohn's disease.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
20.
MODIFIED INFLUENZA B HEMAGGLUTININ POLYPEPTIDES AND NUCLEIC ACIDS AND USES THEREOF
This application relates to modified influenza B hemagglutinin polypeptides and nucleic acids, such as messenger ribonucleic acids (mRNAs), encoding the same, as well as compositions comprising the same, vaccines comprising the same, and methods of using the same, such as in the prevention and/or treatment of diseases or conditions caused by influenza B viruses.
A method for wireless charging of an electronic module of a drug delivery device and to a respective charging system. The method includes the steps of connecting a power source with an oscillator of a charger station, wherein the charger station includes a transmitter side resonator circuit inductively coupled to the oscillator, placing an electronic module having a receiver side resonator circuit inductively coupled to a rectifier connected to a rechargeable battery in a distance from the charger station being equal or less than 15 cm, and tuning or matching the frequency of the transmitter side resonator circuit to the frequency of the receiver side resonator circuit to establish a resonant coupling between the transmitter side resonator circuit and the receiver side resonator circuit for transferring power from the charger station to the electronic module.
A composite image is accessed that comprises a plurality of complex images of samples of a protein-protein complex comprising a first protein and a second protein. The composite image is masked to generate a masked portion and an unmasked portion. A first three-dimensional (3d) shape of the first protein and a second 3d shape of the second protein is accessed. A plurality of docking models are accessed that each define a candidate pose-pair. For each docking model, the first 3d shape, the second 3d shape, and the candidate pose-pair are applied to generate, for the docking model, a corresponding fitment score that describes a goodness-of-fit between the pose-pair and the docking model. One of the docking models is selected as a sensed model for the protein-protein complex based on the fitment scores.
G06T 11/60 - Editing figures and textCombining figures or text
G06V 10/22 - Image preprocessing by selection of a specific region containing or referencing a patternLocating or processing of specific regions to guide the detection or recognition
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
Described is a medicament container carrier adapted to hold a first medicament container having a first predetermined size and capable of containing more than a first volume of a medicament. The container carrier comprises a body, and an adapter coupled to the body. The adapter is adapted to hold a second medicament container having a second predetermined size different from the first predetermined size and capable of containing no more than the first volume of the medicament.
The present technology relates to the field of cancer treatment. In particular, it relates to polypeptides targeting Glypican-3 (GPC3) and T cell receptor (TCR) for use in the treatment of glypican-3-positive (GPC3+) solid tumours, such as hepatocellular carcinoma (HCC) or non-small cell lung cancer (NSCLC). Additionally, it relates to the dosage of said polypeptide when used as treatment.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The disclosure relates to IL-23 receptor inhibitor compounds of formula (I), their pharmaceutical compositions, and their medical uses, for example in the treatment of inflammatory bowel diseases such as Crohn's disease.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of multiple myeloma
27.
Display screen with an animated graphical user interface
The present disclosure relates to an injection device for expelling of a number of preset or user-selectable doses of a medicament, the injection device comprising: an elongated housing extending along a longitudinal axis, and a rotatable member and a counterpart member each comprising a first mechanical code and a second mechanical code, respectively. For setting of a dose the rotatable member is rotatable relative to the housing and relative to the counterpart member. During setting of the dose the rotatable member is constrained along the longitudinal axis relative to the housing or relative to the counterpart member. For expelling of a dose one of the rotatable member and the counterpart member is displaceable along the longitudinal axis into an expelling position relative to the other one of the rotatable member and the counterpart member only when the first mechanical code is aligned with the second mechanical code.
Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
31.
PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS
Provided herein are compounds and pharmaceutical compositions thereof for inhibiting Emopamil Binding Protein (EBP) and their use in the treatment of demyelinating diseases such as multiple sclerosis.
C07D 405/08 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
The present disclosure is generally directed to an attachment mechanism suitable for attaching a module to an object, e.g. to a portion of a drug delivery device. Further, the disclosure is directed to an electronic system, e.g. an electronic add-on module, which is configured to be, e.g. releasably, attached to a drug delivery device as well as an assembly including the electronic add-on module as well as the drug delivery device. The attachment mechanism may include at least one attachment member with a longitudinal axis, an adhesive distal end surface and an opposite adhesive proximal end surface.
Disclosed is a drug delivery device including a housing extending along a longitudinal axis of the drug delivery device, and a distal device portion. The distal device portion includes a distal portion, a proximal portion and at least one intermediate portion. The distal portion includes a distal opening allowing passage of a needle and a bearing surface. The intermediate portion includes at least one wall portion extending proximally from the distal portion to the proximal portion. In at least one state of the drug delivery device, a first radial outer extension of the distal portion in a region axially adjoining the bearing surface is smaller than a second radial outer extension in the intermediate portion, and an outer face of the intermediate portion is inclined relative to the longitudinal axis in a cross section along the longitudinal axis.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
34.
SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present disclosure provides a method for degrading a target protein, comprising: contacting a T-cell with a multispecific binding protein, wherein the multispecific binding protein comprises: a) a first cell surface binding moiety that specifically binds to membrane- bound CTLA-4 on the surface of the T-cell; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein binding of the multispecific binding protein to the membrane-bound CTLA-4 on the surface of the T-cell facilitates the internalization of the target protein by the T-cell. After internalization, the multispecific binding protein plus the target protein traffic to a lysosome within the T-cell, enabling degradation of the target protein within the lysosome. The present disclosure also provides multispecific binding protein compositions, host cells for making the multispecific binding protein compositions, and methods of using the multispecific binding protein compositions to treat disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Compounds are provided which can inhibit KRAS G12D. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers.
A carry case for storing a drug delivery device and to a drug delivery device having a rotatable dose dial member. The case includes an outer shell, and a support recess for receiving and retaining the drug delivery device. In addition, the case further includes a coupling member for mechanically engaging the dose dial member of the drug delivery device, an electrically driven motor, a battery, and a processor connected with the motor and the battery. The coupling member is configured to be driven by the motor to rotate the dose dial member when engaged with the coupling member.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
38.
NATURAL KILLER CELLS AND CD123 NK CELL ENGAGER COMBINATION THERAPY
Provided herein are compositions and methods of treating or preventing a hematological disease or disorder in a subject in need thereof, comprising expanded NK cells and a binding protein comprising a first antigen binding domain with binding specificity to CD123 and a second antigen binding domain with binding specificity to NKp46.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
39.
INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
A liquid medicament administration device includes a body configured to contain and support a medicament container. The body includes an aperture. The aperture includes a viewing window that is coincident with the medicament container when the medicament container is present. The device is configured such that the viewing window is size-adjustable. Also disclosed are associated methods of manufacture.
The present disclosure provides using a double-stranded oligonucleotide compound as a novel therapy to improve the patient reported outcomes and quality of life of patients with hemophilia A or hemophilia B.
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
This disclosure relates to antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV. Also disclosed are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.
In one aspect the present disclosure relates to an imaging arrangement (1) for imaging veins (9) of a human or animal body, the imaging arrangement (1) comprising: - a mount (50) for fastening to a body portion (4) of the human or animal body, - an imaging apparatus (10) movably fastenable to the mount (50), the imaging apparatus (10) comprising: - a scanner (30) operable to scan a scanning area (40) of the body portion (4) and to generate scanner signals when scanning the body portion (4), - a signal processor (22) connected to the scanner (30) and operable to process the scanner signals from the scanner (30) to at least one of extracting or recognizing a structure of interest (19) from the scanner signals, and - a projector (32) connected to the signal processor (22) and operable to project an image (39) of the structure of interest (19) onto a projection area (42) of the body portion (4).
123455, A, and n are defined herein. Also disclosed are methods of preparing such compounds, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory disorders, allergic disorders, skin disorders, mast cell disorders, pain disorders, and itch disorders.
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
46.
PYRIDYL IMIDAZOLES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
122, A, and n are defined herein. Also disclosed are methods of preparing such compounds, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory disorders, allergic disorders, skin disorders, mast cell disorders, pain disorders, and itch disorders.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
A fluid transfer device for transferring a fluid between a diluent container and a medicament container includes a body, a first connecting portion to connect to the diluent container, and a second connecting portion to connect to the medicament container. The first connecting portion includes a first fluid channel to fluidically communicate with an interior of the diluent container, and the second connecting portion comprises a second fluid channel to fluidically communicate with an interior of the medicament container. A third fluid channel is configured to fluidically communicate with the interior of the medicament container and with a pump device. The first fluid channel merges into the second fluid channel to form a first flow path from the diluent container into the medicament container and to form a second flow path from the medicament container into the diluent container.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders; antibodies for medical purposes; pharmaceutical products for treating respiratory diseases; anti-inflammatories; vaccines for human use.
A drug delivery device with an adjustable injection depth comprises a housing, a support element, and a container retaining space for receiving a container comprising a drug. The support element supports the container within the housing, and the drug delivery device comprises a spacer element. In a first state of the drug delivery device, a first axial position of the container relative to the housing is adjusted by the spacer element being in a first spacer position, and in a second state of the drug delivery device, a second axial position of the container is adjusted by the spacer element being in a second position within the housing or being outside of the housing. The first axial position enables a smaller injection depth of a needle coupled to the container compared to the injection depth enabled if the container is in the second axial position.
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
An autoinjector includes a case adapted to hold a medicament container, a needle shroud telescopically coupled to the case, and a plunger slidably disposed in the case. The needle shroud is movable between a first extended position, a retracted position, and a second extended position relative to the case. The plunger is movable between a proximal position, an intermediate position, and a distal position relative to the case. When the plunger is in the intermediate position and the needle shroud is in the retracted position, the plunger abuts the case to prevent the needle shroud from returning to the extended position. When the plunger is in the distal position and the needle shroud is in the second extended position, the plunger abuts the case to prevent the needle shroud from returning to the retracted position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/50 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
68.
IMIDAZO[4,5-D]PYRIDAZINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS
122222367811 is a reactive chemical group. The present invention also relates to a compound of formula A- L1-G-BA (II) wherein G is the product of reaction between RCG1 and a reactive group RCG2 and BA is a binding agent, a pharmaceutical composition comprising it and its therapeutic uses, for instance for treating cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
Systems and devices for producing biological products and methods of using the same are provided. An example universal skid includes a rigid support and a plurality of flow-channel hardware sets. Each flow-channel hardware set couples with a respective flow channel of a plurality of flow channels for unit operations. The flow-channel hardware sets allow the flow channels to operate in parallel or in series for continuous processing over the unit operations. An example modular assembly includes one or more single-use kits for one or more unit operations and a universal skid coupled with the one or more single-use kits. An example manufacturing system includes multiple modular assemblies coupled with each other allowing continuous processing within each modular assembly, in between the modular assemblies, fully continuous processing across multiple unit operations.
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C12M 1/00 - Apparatus for enzymology or microbiology
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Antibodies for medical purposes; Pharmaceutical products for treating respiratory diseases; Anti-inflammatories; Vaccines for human use
Provided are methods for identifying and treating patients with cancer, where the cancer expresses CEACAM5. The methods include measuring circulating CEA to identify patients likely to benefit from treatment with an agent specific for CEACAM5. Such patients can have high circulating CEA and only low or medium expression of CEACAM5 on tumor cells as measured by immunohistochemistry (IHC). The agent specific for CEACAM5 can be tusamitamab ravtansine. Such agent can be used in combination with one or more additional agents to treat the cancer. In certain embodiments the cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A drug delivery arrangement includes a drug delivery device with a housing adapted to receive a needle that is configured to pierce a skin of a user. The drug delivery device comprises a drive energy source, and is configured to perform a drug delivery operation using the energy obtainable from the drive energy source. The drug delivery device is an autoinjector. An injection depth adjusting member is connectable to or connected to a device member of the drug delivery device. The injection depth adjusting member is configured to provide an adjuster bearing surface with which the drug delivery arrangement bears on the skin during use when the injection depth adjusting member is connected to the device member. When connected to the device member, the injection depth adjusting member is configured to define the injection depth by which the needle can penetrate the skin.
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/34 - Constructions for connecting the needle
99.
ASSEMBLY FOR AN INJECTION DEVICE, INJECTION DEVICE COMPRISING SUCH AN ASSEMBLY, MEDICAMENT CONTAINER FOR SUCH AN ASSEMBLY, AND METHOD FOR PRODUCING SUCH A MEDICAMENT CONTAINER
The present disclosure concerns an assembly for an injection device, e.g. an auto-injector device, comprising: a medicament container comprising a medicament container body and a needle protruding from a distal end of the medicament container body and fluidly connected to an interior of the medicament container body, a housing comprising a first bearing surface configured to support the medicament container in a distal direction, a distancing element arranged on the needle and providing a second bearing surface configured to contact a patient's skin during use of the injection device, thereby preventing insertion of the needle into the patient's body beyond a predetermined injection depth.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/34 - Constructions for connecting the needle
100.
DRUG DELIVERY ARRANGEMENT COMPRISING A TISSUE RECEIVING ELEMENT
A drug delivery arrangement (1) comprising a drug delivery device (2), having a housing (3), and a needle, and a tissue receiving element (6), having a needle passage opening (7) and a tissue receiving portion (8), wherein the tissue receiving element is configured to interact with the skin (9) in order to lift tissue into the tissue receiving portion to reduce the risk of injury due to deep punctures.
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
